81 research outputs found

    Plant Establishment in Masticated Utah Juniper Woodlands

    Get PDF
    Juniper (Juniperus spp.) encroachment into sagebrush (Artemisia spp.)-bunchgrass communities has reduced understory cover on millions of hectares of semiarid rangelands. Mechanical masticators shred trees to restore desirable vegetation and reduce the potential for catastrophic wildfire. Mechanical mastication where juniper density is high and perennial grass cover is low brings a risk of invasive weed dominance unless perennial species are established. To determine whether juniper mastication favors annual- or perennial-grass establishment, we compared seedling emergence, tillers, and aboveground biomass of cheatgrass (Bromus tectorum L.) and Anatone bluebunch wheatgrass (Pseudoroegneria spicata [Pursh] A. Löve). Comparisons were made among hand-planted rows between and under juniper canopies of masticated and adjacent untreated control areas at three locations in Utah. Bluebunch wheatgrass had 16% (95% CI: 11–21) and cheatgrass had 10% (95% CI: 5–15) fewer seedlings emerge per row in masticated than untreated areas (P \u3c 0.001). However, bluebunch wheatgrass had 3.2 (95% CI: 2.0–5.2) times more tillers and 1.9 (95% CI: 1.6–2.2) times more aboveground biomass per row in masticated than untreated areas (P \u3c 0.001). Similarly, cheatgrass had 2.3 (95% CI: 1.5–3.8) times more tillers, 2.0 (95% CI: 1.7–2.4) times more aboveground biomass, and 11.4 (95% CI: 6.3–20.7) times more spikelets per row in masticated than untreated areas (P \u3c 0.001). This increased seedling growth in masticated areas was associated with increased inorganic nitrogen and soil water compared to untreated areas. Because mastication improves the growth of both cheatgrass and bluebunch wheatgrass seedlings, it could support dominance by either annual- or perennial-life forms. To avoid cheatgrass dominance where perennial understory cover is limited and cheatgrass propagule pressure is high, mastication should be accompanied by seeding desirable perennial species such as Anatone bluebunch wheatgrass

    Tree Reduction and Debris From Mastication of Utah Juniper Alter the Soil Climate in Sagebrush Steppe

    Get PDF
    Juniper (Juniperus spp.) trees are masticated to reduce canopy fuel loads and the potential for crown fire. We determined the effects of tree reduction and soil cover in the forms of tree mounds and masticated debris on hourly soil water potential and soil temperature at 1–30 cm soil depth. Measurements were made in masticated and untreated areas at three sites in the western Utah portion of the Great Basin. Cumulative seasonal-response variables included wet days (\u3e−1.5 MPa), degree days (\u3e0 °C), and wet degree days (\u3e−1.5 MPa and \u3e0 °C). Masticated areas had 27 more wet days (P \u3c 0.001), 32 more degree days (P = 0.007), and 311 more wet degree days (P \u3c 0.001) than untreated areas across soil depths and seasons. Soil cover had less influence on these soil climate variables than tree reduction. Most importantly, tree reduction increased wet days (P \u3c 0.001) by an average of 44.5 days during the spring and summer growing seasons at depths of 13–30 cm. Managers are advised to masticate trees while desired understory cover remains high in order to minimize water available to weeds

    Mechanical Mastication of Utah Juniper Encroaching Sagebrush Steppe Increases Inorganic Soil N

    Get PDF
    Juniper (Juniperus spp.) has encroached on millions of hectares of sagebrush (Artemisia spp.) steppe. Juniper mechanical mastication increases cover of understory species but could increase resource availability and subsequently invasive plant species. We quantified the effects of juniper mastication on soil resource availability by comparing total C, total N, C : N ratio, Olsen extractable P, sulfate S, and pH using soil samples and inorganic N (NO3-+NH4+) using ion exchange membranes. We compared resource availability in paired masticated and untreated areas in three juniper-dominated sagebrush and bunchgrass ecosystems in the Utah portion of the Great Basin. Inorganic N was 4.7 times higher in masticated than in untreated areas across seasons (PP

    Treatment Longevity and Changes in Surface Fuel Loads After Pinyon–Juniper Mastication

    Get PDF
    In the Intermountain West, land managers masticate pinyon pine (Pinus spp.) and juniper (Juniperus spp.) trees that have encroached sagebrush steppe communities to reduce canopy fuels, alter potential fire behavior, and promote growth of understory grasses, forbs, and shrubs. At three study sites in Utah, 45 sampling plots spanning a range of tree cover from 5% to 50% were masticated. We measured surface fuel load components three times over a 10‐yr period. We also measured tree cover, density, and height as indicators of treatment longevity. Changes in these variables were analyzed across the range of pre‐treatment tree cover using linear mixed effects modeling. We detected decreases in 1‐h down woody debris by 5–6 yr post‐treatment, and from 5–6 to 10 yr post‐treatment, but did not detect changes in 10‐h or 100 + 1000‐h down woody debris. By 10 yr post‐treatment, there was very little duff and tree litter left for all pre‐treatment tree cover values. Herbaceous fuels (all standing live and dead biomass) increased through 10 yr post‐treatment. At 10 yr post‐treatment, pinyon–juniper cover ranged 0–2.6%, and the majority of trees were1‐h fuels were the only class of down woody debris that decreased, it may be beneficial to masticate woody fuels to the finest size possible. Decreases in 1‐h down woody debris and duff + litter fuels over time may have important implications for fire behavior and effects, but increases in herbaceous and shrub fuel loads should also be taken into account. At 10 yr post‐treatment, understory grasses and shrubs were not being outcompeted by trees, and average pinyon–juniper canopy cover wa

    Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial.

    Get PDF
    BACKGROUND: Observational research suggests that combined therapy with Vitamin C, thiamine and hydrocortisone may reduce mortality in patients with septic shock. METHODS AND DESIGN: The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial is a multicenter, double-blind, adaptive sample size, randomized, placebo-controlled trial designed to test the efficacy of combination therapy with vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) given every 6 h for up to 16 doses in patients with respiratory or circulatory dysfunction (or both) resulting from sepsis. The primary outcome is ventilator- and vasopressor-free days with mortality as the key secondary outcome. Recruitment began in August 2018 and is ongoing; 501 participants have been enrolled to date, with a planned maximum sample size of 2000. The Data and Safety Monitoring Board reviewed interim results at N = 200, 300, 400 and 500, and has recommended continuing recruitment. The next interim analysis will occur when N = 1000. This update presents the statistical analysis plan. Specifically, we provide definitions for key treatment and outcome variables, and for intent-to-treat, per-protocol, and safety analysis datasets. We describe the planned descriptive analyses, the main analysis of the primary end point, our approach to secondary and exploratory analyses, and handling of missing data. Our goal is to provide enough detail that our approach could be replicated by an independent study group, thereby enhancing the transparency of the study. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03509350. Registered on 26 April 2018

    Differential Spinal and Supraspinal Activation of Glia in a Rat Model of Morphine Tolerance

    Get PDF
    Development of tolerance is a well known pharmacological characteristic of opioids and a major clinical problem. In addition to the known neuronal mechanisms of opioid tolerance, activation of glia has emerged as a potentially significant new mechanism. We studied activation of microglia and astrocytes in morphine tolerance and opioid-induced hyperalgesia in rats using immunohistochemistry, flow cytometry and RNA sequencing in spinal-and supraspinal regions. Chronic morphine treatment that induced tolerance and hyperalgesia also increased immunoreactivity of spinal microglia in the dorsal and ventral horns. Flow cytometry demonstrated that morphine treatment increased the proportion of M2-polarized spinal microglia, but failed to impact the number or the proportion of M1-polarized microglia. In the transcriptome of microglial cells isolated from the spinal cord (SC), morphine treatment increased transcripts related to cell activation and defense response. In the studied brain regions, no activation of microglia or astrocytes was detected by immunohistochemistry, except for a decrease in the number of microglial cells in the substantia nigra. In flow cytometry, morphine caused a decrease in the number of microglial cells in the medulla, but otherwise no change was detected for the count or the proportion of M1-and M2-polarized microglia in the medulla or sensory cortex. No evidence for the activation of glia in the brain was seen. Our results suggest that glial activation associated with opioid tolerance and opioid-induced hyperalgesia occurs mainly at the spinal level. The transcriptome data suggest that the microglial activation pattern after chronic morphine treatment has similarities with that of neuropathic pain. (C) 2018 IBRO. Published by Elsevier Ltd. All rights reserved.Peer reviewe

    Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial

    Get PDF
    Importance: Sepsis induces profound metabolic derangements, while exogenous levocarnitine mitigates metabolic dysfunction by enhancing glucose and lactate oxidation and increasing fatty acid shuttling. Previous trials in sepsis suggest beneficial effects of levocarnitine on patient-centered outcomes. Objectives: To test the hypothesis that levocarnitine reduces cumulative organ failure in patients with septic shock at 48 hours and, if present, to estimate the probability that the most efficacious dose will decrease 28-day mortality in a pivotal phase 3 clinical trial. Design, Setting, and Participants: Multicenter adaptive, randomized, blinded, dose-finding, phase 2 clinical trial (Rapid Administration of Carnitine in Sepsis [RACE]). The setting was 16 urban US medical centers. Participants were patients aged 18 years or older admitted from March 5, 2013, to February 5, 2018, with septic shock and moderate organ dysfunction. Interventions: Within 24 hours of identification, patients were assigned to 1 of the following 4 treatments: low (6 g), medium (12 g), or high (18 g) doses of levocarnitine or an equivalent volume of saline placebo administered as a 12-hour infusion. Main Outcomes and Measures: The primary outcome required, first, a greater than 90% posterior probability that the most promising levocarnitine dose decreases the Sequential Organ Failure Assessment (SOFA) score at 48 hours and, second (given having met the first condition), at least a 30% predictive probability of success in reducing 28-day mortality in a subsequent traditional superiority trial to test efficacy. Results: Of the 250 enrolled participants (mean [SD] age, 61.7 [14.8] years; 56.8% male), 35, 34, and 106 patients were adaptively randomized to the low, medium, and high levocarnitine doses, respectively, while 75 patients were randomized to placebo. In the intent-to-treat analysis, the fitted mean (SD) changes in the SOFA score for the low, medium, and high levocarnitine groups were -1.27 (0.49), -1.66 (0.38), and -1.97 (0.32), respectively, vs -1.63 (0.35) in the placebo group. The posterior probability that the 18-g dose is superior to placebo was 0.78, which did not meet the a priori threshold of 0.90. Mortality at 28 days was 45.9% (34 of 74) in the placebo group compared with 43.3% (45 of 104) for the most promising levocarnitine dose (18 g). Similar findings were noted in the per-protocol analysis. Conclusions and Relevance: In this dose-finding, phase 2 adaptive randomized trial, the most efficacious dose of levocarnitine (18 g) did not meaningfully reduce cumulative organ failure at 48 hours

    Approximation of substantive criminal law in the EU

    Get PDF
    This book dedicated to the substantive criminal law in the EU put the Libson Treaty under scrutiny. It evaluates the changes introduced by this new Treaty and their impact, before reflecting on future prospects
    corecore